Medpage Today on MSN5d
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free SurvivalAdding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
As it turned out, adding spartalizumab to treatment with the two targeted drugs failed to provide ... to market well behind other PD-1/PD-L1 checkpoint inhibitors – that piggybacking on its ...
BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...
During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...
Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...
The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback